Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
  • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
  • C07D213/30—Oxygen atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C255/00—Carboxylic acid nitriles
  • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
  • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
  • C07C255/37—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by etherified hydroxy groups
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
  • C07C39/205—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic parts with unsaturation outside the rings
  • C07C39/21—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic parts with unsaturation outside the rings with at least one hydroxy group on a non-condensed ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
  • C07C39/24—Halogenated derivatives
  • C07C39/373—Halogenated derivatives with all hydroxy groups on non-condensed rings and with unsaturation outside the aromatic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C43/00—Ethers; Compounds having groups, groups or groups
  • C07C43/02—Ethers
  • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
  • C07C43/215—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
  • C07C59/40—Unsaturated compounds
  • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
  • C07C59/52—Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
  • C07C69/017—Esters of hydroxy compounds having the esterified hydroxy group bound to a carbon atom of a six-membered aromatic ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
  • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
  • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
  • C07D307/40—Radicals substituted by oxygen atoms
  • C07D307/42—Singly bound oxygen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
  • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
  • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
  • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
  • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
  • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms

Definitions

• Stilbene derivatives have been shown to have a wide range activities and are widely distributed in nature as natural constituentes of plants. There is a growing interest in stilbene derivatives because of a range of activities that have been observed in some of the naturally occurring as well as some of the synthetic stilbenes. Activities include antibiotic (Hu, K., et al., Canadian Journal of Microbiology, 1998, 44, 1072), antileukemic (Mannila, et al., Phytochemistry, 1993, 33, 813), carcinnostatic (EP 641, 767), and protein-tyrosine kinase inhibitory activity (Thakkar, K.; et al., J. Med. Chem., 1993, 36,2950).
• T lymphocytes play an important role in regulating the immune response.
• T-cells are closely associated with a wide variety of cytokines such as interleukines (IL), tumor necrosis factors (TNF), interferons (IFN) and granulocyte macrophage colony.
• IL interleukines
• TNF tumor necrosis factors
• IFN interferons
• granulocyte macrophage colony a wide variety of cytokines
• T-cell activation and proliferation, and the cytokines associated with them mediate a wide range of physiological activities in the immune system and in pathogenic inflammation.
• inhibitors of certain ILs are potentially beneficial for Th2 predominant diseases, while inhibitors of IFN- ⁇ and TNF- ⁇ are useful for treatment of Th1 induced immune diseases.
• Macrophages are very important components of the host defense system, but they are also involved in the development of tissue injury during inflammation in some human disease. Efficient antagonists can block subsequent symptoms (skin redness, edema, pain and dysfunction) of inflammation.
• CD86 expression, nitric oxide and TNF- ⁇ production are experimental indicators of macrophage function in vivo. CD86 expression by antigen presenting cells including dendritic cells, macrophages and activated B cells is necessary for interaction with T-cell CD28, which is necessary for the T-cells to be fully activated.
• Nitric oxide is a potent microbiological macrophage product.
• TNF- ⁇ is a pro-inflammatory cytokine important in recruitment and stimulation of inflammatory cells.
• IL-8 is a chemokine produced by neutrophils that in addition to being chemotactic for monocytes and other leukocytes, also activates neutrophils. Down-regulation of neutrophil IL-8 generation may represent a negative feedback mechanism helping to control neutrophil inflammatory activity by preventing further neutrophil recruitment and activation.
• cytokines mediate a broad inflammatory and immune response as a result of infection or injury and/or other factors.
• Other cytokines have more specific functions.
• the complex interplay of these many different cytokine functions with immune cells is essential for the appropriate and optimal immune function.
• Activation of T-cells is often the initiating event in many of the immune, inflammatory and autoimmune diseases. Accordingly, compounds that can effectively interfere with cytokine formation have utility in preventing and treating related disorders.
• IL-2 a 15-kDa protein, is secreted by T-cells upon antigen stimulation and is required for normal immune responsiveness. IL-2 stimulates the proliferation and activation of B and T-cells and is a potent cytokine that can lead to cellular activation and proliferation. IL-2 receptors are found on activated B-Cells, lipolysaccharide treated monocytes, and many T-cells. Clinical studies have shown that interference with IL-2 activity effectively suppresses immune response in vivo [T. A. Waldmann, Immunol. Today, 14, 270 (1993)].
• IL-8 interleukin-8
• neutrophil activating peptide or monocyte derived neutrophil activating peptide. It attracts neutrophils by chemotaxis and triggers the release of myeloperoxidase.
• IL-8 is believed to be associated with diseases such as psoriasis, allergic reactions, rheumatic afflictions and inflammations of the skin and the lungs.
• IFN- ⁇ is a member of the interferon family and was produced originally upon mitogenic induction of lymphocytes. IFN- ⁇ is secreted from CD4+Th1 cells, CD8 cells, gamma/delta T-cells and activated natural killer cells. It plays a role in activating lymphocytes to enhance anti-microbial and anti-tumor effects. In addition, it plays a role in regulating the proliferation, differentiation, and response of lymphocyte subsets. IFN- ⁇ is synthesized by lymphocytes in response to mitogens and induces major histocompatibility complex (MHC) Class II antigen expression. IFN- ⁇ promotes a number of pro-inflammatory aspects of immune responses including the up-regulation of MHC. For a number of autoimmune diseases, the disease-associated inflammatory process is associated with an increased availability of IFN- ⁇ . IFN- ⁇ may have a strong impact on autoimmune disease progression or resolution, actions that may be specific for a particular condition.
• MHC major histocompatibility complex
• R 2 and R 3 are independently selected from a group consisting of a). H, b).
• R 4 and R 5 are independently each selected from the group consisting of a). H, b). unsubstituted or substituted alkyl, cycloalkyl, aryl or aralkyl, and c).
• R 6 is selected from a). H, b).unsubstituted or subustituted alkyl, cycloalkyl, aryl or aralkyl.
• R 7 and R 8 are independently selected from a group consisting of a). H, b). unsubstituted or substituted alkyl, cycloalkyl, aryl or aralkyl.
• R 9 is selected from a). H, b). unsubstituted or substituted alkyl, cycloalkyl, aryl, or aralkyl and c). NR 7 R 8 .
• R 10 is selected from a). H, b).
• R 11 is selected from a). H and b). unsubstituted or substituted alkyl, cycloalkyl, aryl or aralkyl.
• Ar is selected from a). unsubstituted, mono or multi-substituted phenyl with proviso that R 2 and R 3 cannot be H simultaneously. b). unsubstituted, mono or multi-substituted five-member heterocyclic ring containing O, S and/or N and c).
• Ar is selected from a). Unsubstituted, mono or multi-substituted phenyl with the proviso that R 2 and R 3 cannot be H simultaneously; b). Unsubstituted, mono or multi-substituted five-member heterocyclic ring containing O, S and/or N, c). Unsubstituted, mono or multi-substituted six-member heterocyclic ring containing O, S and/or N.
• this present invention provides the use of the compounds of Formula I as modulators of T-cells, neutrophils, macrophages and their associated cytokines, and particularly as agents for treating inflammatory and auto-immune diseases.
• This invention also relates to the pharmaceutical composition comprising a compound of the invention and/or salt thereof.
• this invention relates to the process for making compounds of Formula I
• substitutes for R 6 is selected from a). H, b).unsubstituted or subustituted alkyl, cycloalkyl, aryl or aralkyl.
• substitutes for R 7 and R 8 are independently selected from a group consisting of a). H, b). unsubstituted or substituted alkyl, cycloalkyl, aryl or aralkyl.
• substitutes for R 9 is selected from a). H, b).
• R 10 is selected from a). H, b). unsubstituted or substituted alkyl, cycloalkyl, aryl, or aralkyl and c).
• R 11 is selected from a). H and b). unsubstituted or substituted alkyl, cycloalkyl, aryl or aralkyl.
• Ar is selected from a). unsubstituted, mono or multi-substituted phenyl with proviso that R 2 and R 3 cannot be H simultaneously. b).
• the compounds of the present invention have trans and cis (E and Z) isomers. All stereoisomers of the present compounds, such as those which may exist including trans, cis, forms, are contemplated within the scope of this invention. Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed.
• Preferred compounds are those wherein R 4 and R 5 are hydrogen, methyl and acetyl. Particularly preferred compounds are those wherein R 1 is hydrogen or an alkyl group, R 4 and R 5 are hydrogen, methyl and acetyl. Highly preferred compounds are the following:
• salts denotes acidic and/or basic salts, formed with inorganic and/or organic acids and bases. Suitable acids include, for example, hydrochloric, sulfuric, nitric, benzenesulfonic, acetic, maleic, tartaric and the like which are pharmaceutically acceptable. It is well known to one skilled in the art that an appropriate salt is chosen based on physical and chemical stability, flowability, hydroscopicity and solubility. While pharmaceutically acceptable salts are preferred, particularly when employing the compounds of the invention as medicaments, other salts find utility, for example, in processing these compounds, or where non-medicament-type uses are contemplated.
• compounds of this present invention of Formula I are useful as modulators of T-cells, neutrophils, macrophages and their associated cytokines, are of use to conditions mediated by these cells and cytokines.
• the indications for which the inventive compounds are of use include in particular, autoimmune and inflammatory conditions and conditions associated with or causal to transplant rejection.
• Use of the compounds of the present invention includes treatment (including amelioration, reduction, elimination or cure of etiology or symptoms) and/or prevention (including substantial or complete restriction, prophylaxis or avoidance) of disorders associated with the above mentioned activities.
• Such use is exemplified by, but is not limited to, treating and or preventing a range of disorders such as: transplant [such as organ transplant, acute transplant or heterograft or homograft (such as is employed in burn treatment)] rejection; protection from ischemic or reperfusion injury such as ischemic or reperfusion injury incurred during organ transplantation, myocardial infarction, stroke or other causes; transplantation tolerance induction; arthritis (such as rheumatoid arthritis, psoriatic arthritis or osteoarthritis); multiple sclerosis; inflammatory bowel disease, including ulcerative colitis and Crohn's disease; lupus (systemic lupus erythematosis); graft vs.
• transplant such as organ transplant, acute transplant or heterograft or homograft (such as is employed in burn treatment)
• protection from ischemic or reperfusion injury such as ischemic or reperfusion injury incurred during organ transplantation, myocardial infarction, stroke or other causes
• transplantation tolerance induction
• T-cell mediated hypersensitivity diseases including contact hypersensitivity, delayed-type hypersensitivity, and gluten-sensitive enteropathy (Celiac disease); psoriasis; contact dermatitis (including that due to poison ivy); Hashimoto's thyroiditis; Sjogren's syndrome; Autoimmune Hyperthyroidism, such as Graves' Disease; Addison's disease (autoimmune disease of the adrenalglands); Autoimmune polyglandular disease (also known as autoimmune polyglandular syndrome); autoimmune alopecia; pernicious anemia; vitiligo; autoimmune hypopituatarism; Guillain-Barre syndrome; other autoimmune diseases; glomerulonephritis, serum sickness; uticaria; allergic diseases such as respiratory allergies (asthma, hay fever, allergic rhinitis) or skin allergies; scleracierma; mycosis fungoides; acute inflammatory responses (such as acute respiratory distress syndrome and ishchemia/reperfusion injury); der
• the present invention also provides use of the inventive compounds for treating and preventing the aforementioned disorders such as atopic.
• the compounds of the present invention are useful in degranulation of mast cells and basophils that plays an important role in asthma, allergic rhinitis, and other allergic disease.
• Compounds of the present invention that block neutrophil activation are useful, for example, in the treatment of ischemia and reperfusion injury.
• Compounds of the present invention inhibit induced degranulation and this ability results in additional anti-inflammatory activity for the present compounds beyond their effect on T-cells and neutrophils.
• the present compounds are of value for the treatment of asthma, allergic rhinitis, and other instances of allergic disease.
• the combined activity of the present compounds towards macrophages, neutrophils and T-cells may be of value in the treatment of any of the aforementioned disorders.
• the compounds of the present invention are useful for the treatment of the aforementioned exemplary disorders irrespective of their etiology, for example, for the treatment of transplant rejection, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, lupus, systemic lupus erythematosis, graft vs host disease, T-cell mediated hypersensitivity disease, psoriasis, restenosis, surgical adhesions, tuberculosis, and chronic inflammatory lung diseases (e.g., asthma, pneumoconiosis, chronic obstructive pulmonary disease, nasal polyps and pulmonary fibrosis).
• Hashimoto's thyroiditis Guillain-Barre syndrome, cancer, contact dermatitis, allergic disease such as allergic rhinitis, asthma, ischemic or reperfusion injury, or atopic dermatitis.
• the present invention provides use of compounds of the present invention in combination with other therapeutic agents.
• Other therapeutic agents known to those skilled in the art such as cyclosporin A, FK506 and rapamycin, may be employed with the inventive compounds in the present invention.
• such other therapeutic agent(s) may be administered prior to, simultaneously with or following the administration of the compound(s) of the present invention.
• the present invention also provides pharmaceutical compositions comprising of at least one of the compounds of Formula I capable of treating the aforementioned disorders in an amount effective therefore, and in a pharmaceutically acceptable vehicle or diluent.
• the compositions of the present invention may contain other agents that are known to those skilled in the art, and may be formulated, for example, by employing conventional solid or liquid vehicles or diluents, as well as pharmaceutical additives of a type appropriate to the mode of desired administration (for example, excipients, binders, preservatives, stabilizers, flavors, etc.) according to techniques such as those well known in the art of pharmaceutical formulation.
• compositions of the present invention containing the active ingredient may be in a form suitable for systemic, oral and/or topical use.
• the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension.
• This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents that have been mentioned above.
• the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol.
• the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
• sterile, fixed oils are conventionally employed as a solvent or suspending medium.
• any bland fixed oil may be employed including synthetic mono- or diglycerides.
• fatty acids such as oleic acid find use in the preparation of injectables.
• Compounds of Formula I may also be formulated in the form of suppositories for rectal administration of the drug.
• These compositions can be prepared by mixing the drug with a suitable nonirritating excipient that is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
• suitable nonirritating excipient that is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
• Such materials are cocoa butter and polyethylene glycols.
• compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients that are suitable for the manufacture of tablets.
• excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc.
• the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
• a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.
• the pharmaceutical compositions of the invention also may be in the form of oil-in-water emulsions.
• the oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these.
• Suitable emulsifying agents may be naturally-occurring phosphatides, for example soybean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate.
• the emulsions may also contain sweetening and flavouring agents.
• Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations also may contain a demulcent, a preservative and flavoring and coloring agents.
• sweetening agents for example glycerol, propylene glycol, sorbitol or sucrose.
• Such formulations also may contain a demulcent, a preservative and flavoring and coloring agents.
• topical use creams, ointments, jellies, solutions or suspensions, etc., containing the compound of Formula I is employed.
• topical application shall include mouth washes and gargles.
• Preparation of such topical formulations are well described in the art of pharmaceutical formulations as exemplified by Remington's Pharmaceutical Science, Edition 17, Mack Publishing Company, Easton, Pa.
• these compounds also could be administered as a powder or spray, particularly in aerosol form.
• Dosage levels in the order of about 0.01 mg to about 140 mg/kg of body weight per day are useful in the treatment of the above-indicated conditions, or alternatively about 0.5 mg to about 7 g per patient per day.
• inflammation may be effectively treated by the administration of about 0.01 to 50 mg of the compound per kilogram of body weight per day, or alternatively about 0.5 mg to about 3.5 g per patient per day, preferably 2.5 mg to 1 g per patient per day.
• the specific dose level for any particular patient will depend upon a variety of factors including the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.
• the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
• a formulation intended for oral administration of humans may contain from 0.5 mg to 5 g of active agent compounded with an appropriate and convenient amount of carrier material that may vary from about 5 to about 95 percent of the total composition.
• Dosage unit forms will generally contain between about 1 mg to about 500 mg of an active ingredient, typically 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, or 1000 mg.
• the present invention also provides process of making compounds of the invention.
• the compounds of this invention may be synthesized by the synthetic methods as described by Webster et al., WO 01/42231, and other related literatures (Treadwell et al. J. Org. Chem. 1999 (64), 8718-8723; Hashimoto et al., WO 1994/020456), which can be generalized easily. Further, alternative methods or modifications may be used. Examples given herein are for illustration purposes only and are not considered as limitations of this invention.
• the stilbene structures of the compounds of the invention may be synthesized via the following reaction outlined by schemes 1-3:Wittig olefination (Scheme 1), Grignard reaction (Scheme 2) and condensation (Scheme 3).
• T-cell assay is commonly employed as a primary platform for testing of activities that modulate immune and inflammatory activities in many diseases. Assays of antigen non-specific T-cell proliferation and antigen-specific proliferation are often used in the tests.
• Feeder cells were prepared by treating BALB/C spleen cells with mitomycin C (50 ⁇ g/ml, for 20 min at 37° C.) followed by five times washing using a large volume of Hank's solution.
• C57BL/6 Responders (2 ⁇ 10 5 ) was incubated in duplicate with the mitomycin C treated BALB/C feeder cells (2 ⁇ 10 5 ) in 96-well, round-bottomed, microtitre plates (Costar Laboratories, Worcester, Mass.) with complete medium (RPMI 1640 with 25 mM Hepes and L-glutamine supplemented with 5 ⁇ 10 5 M 2-mercapto-ethanol, 10% fetal cow serum (FCS), 10,000 unit of penicillin, and 10 mg of streptomycin per 100 ml of medium) at 37° C., 5% CO 2 .
• FCS fetal cow serum
• streptomycin per 100 ml of medium
• the culture wells received [ 3 H]thymidine ([ 3 H]TdR; 1 ⁇ Ci/well) and proliferation was assessed at 16 h by harvesting cells onto glass fiber filter paper and counting in a ⁇ -counter.
• T-cells were activated by concanavalin A (Con A) and incubated, cytokines in the supernatants were assayed by commercial immune-linked immunosorbent assay (ELISA) kits.
• Con A concanavalin A
• ELISA commercial immune-linked immunosorbent assay
• Macrophages are very important components of the host defense system, but they are also involved in the development of tissue injury during inflammation in some human disease. Efficient antagonists can block subsequent symptoms (skin redness, edema, pain and dysfunction) of inflammation.
• CD86 expression, nitric oxide and TNF- ⁇ production are experimental indicators of macrophage function in vivo. CD86 expression by antigen presenting cells, including dendritic cells, macrophages and activated B cells, is necessary for interaction with T-cell CD28, which is necessary for T-cells to be fully activated.
• Nitric oxide is a potent microbiological macrophage product.
• TNF ⁇ is a pro-inflammatory cytokine important in recruitment and stimulation of inflammatory cells.
• Murine macrophage cells were lifted from adherent culture and resuspended in 10% FCS in DMEM. Cells (5 ⁇ 10 4 /well) were aliquoted into flat bottom, tissue culture-treated microtitre plates and lipolysaccharide. N-acetylcysteine test compound, or vehicle controls were added. The cells were incubated at 37° C., 5% CO 2 for 24 h and the culture supernatant removed for TNF- ⁇ ELISA, and CD86 expression was determined by FACS analysis on flow cytometer.
• Neutrophils were prepared from freshly collected human citrated whole blood. Briefly, 400 ml of blood were mixed with 80 ml of 4% dextran in Hanks buffered saline solution (HBSS) pH 7.4 and allowed to settle for 1 hour. Plasma was collected continuously and 5 ml applied to 5 ml of Ficoll Paque (Pharmacia) in 15 ml polypropylene tubes. Following centrifugation at 500 g for 30 minutes, the neutrophil pellets were washed free of erythrocytes by 20 seconds of hypotonic shock. Neutrophils were resuspended in HBSS, kept on ice and used for experiments within .3 h. Neutrophil viability and purity was always greater than 90%.
• HBSS Hanks buffered saline solution
• Histamine is an important mediator and is involved in a wide range of biological activities, including inflammation and allergy.
• the activity of representative compounds, against histamine release was tested using a standard mast cell assay (Arquardt, C. et. al. 1986. Am Rev Respir Dis 133:1105-1109).
• the mast cells were derived from mouse bone marrow.
• the histamine release was measured by the hexosamindase activity.
• Table 9 summarizes the activity of 2-i-Propyl-5-(2-thiophene-2-ylethenyl)-1,3-benzenediol. TABLE 9 Effect of test compounds on histamine release by mast cells.
• Compound IC 50 ( ⁇ M) 2-i-Propyl-5-(2-thiophene-2-ylethenyl)-1,3-benzenediol 18.9
• mice ear edema was induced by phorbol-12-myristate-13-acetate (TPA) by adding 20 ul of 0.01% (w/v) to the right ear of each mouse.
• TPA phorbol-12-myristate-13-acetate
• Each test compound dissolved in the same vehicle (ethanol) as TPA was applied separately to the right ear of each moue.
• the mouse ear edema of each test compound was compared with that of the TPA and expressed as % of inhibition.
• This material was prepared as a 20% yield from methyl 3,5-dimethoxy-4-i-propylbenzoate and 4-methylbenzyl bromide using the same method as described in example 1 (b).
• This material was prepared in a total yield of 78% from 1,3-bis(3-fluorophenyl)-2-(3,5-dimethoxy-4-i-propylphenyl)propan-2-ol and pyridine hydrochloride using the same method as described in example 2(b).
• This material was prepared in a yield of 70% as a Z/E mixture from 1,3-bis(3,5-difluorobenzyl)-2-(3,5-dimethoxy-4-i-propylphenyl)propan-2-ol obtained above and pyridine hydrochloride using the same method as described in example 2 (b).
• This compound was prepared from 2-(3,5-dimethoxy-4-i-propylphenyl)-1,1-diphenyl ethanol obtained above and BBr 3 by the same procedure as described in example 1(c).
• This compound was prepared from 3,5-dimethoxy-4-i-propylbenzyl aldehyde obtained above and benzylnitrile by the same procedure as described in example 6 (d).
• This compound was prepared from 3-(3,5-dimethoxy-4-i-propylphenyl)-2-phenylpropenylnitrile (9) and Pyridine hydrochloride by the same procedure as described in example 2 (b).
• This compound was made from 1-(3,5-dimethoxy-4-i-propylphenyl)-2-phenylpropene (11) and BBr 3 in 63% yield by the same procedure as described in example 1(c).
• This compound was made from 1-(3,5-dimethoxyphenyl)-2-phenylpropene (13). and BBr 3 . in 63% yield by the same procedure as described in Example 1(c).
• This material was prepared from 15 obtained in Example 15(b) and BBr 3 in 27% yield as the similar way as described in example 1 (d) , except that 6NHCl was added to ether extract to precipitate 16 out as a hydrochloride salt.
• This material was prepared from diethyl (3,5-dimethoxy-4-i-propylbenzyl)phosphonate obtained in Example 15(a) and thiophene carboxaldehyde in 78% yield as the same way as described in the example 15(b),
• This material was prepared from 2-[2-(3.5-dimethoxy-4-i-propylphenyl)ethenyl]thiophene obtained in example 17 and pyridine hydrochloride in 24% yield as the same way as described in example 2(b).
• This material was prepared from diethyl (3,5-dimethoxy-4-i-propylbenzyl)phosphonate prepared in example 15(a) and 2-furaldehyde in 56% yield by the same procedure as described in example 15(b).

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Immunology (AREA)
• Pain & Pain Management (AREA)
• Rheumatology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Pyridine Compounds (AREA)
• Heterocyclic Compounds Containing Sulfur Atoms (AREA)
• Furan Compounds (AREA)

Priority Applications (2)

Applications Claiming Priority (6)

Related Child Applications (1)

Publications (1)

Family

ID=26949001

Family Applications (2)

Family Applications After (1)

Country Status (10)

Cited By (1)

Families Citing this family (16)

Citations (2)

Family Cites Families (39)

• 2002
  • 2002-01-17 ES ES02716007T patent/ES2401077T3/es not_active Expired - Lifetime
  • 2002-01-17 CN CN200910001412.6A patent/CN101434517B/zh not_active Expired - Lifetime
  • 2002-01-17 KR KR1020027012338A patent/KR100836207B1/ko active IP Right Grant
  • 2002-01-17 AU AU2002226225A patent/AU2002226225B2/en not_active Expired
  • 2002-01-17 WO PCT/CA2002/000059 patent/WO2002057219A1/en active Application Filing
  • 2002-01-17 US US10/466,879 patent/US20040102517A1/en not_active Abandoned
  • 2002-01-17 CN CNB028001214A patent/CN100462354C/zh not_active Expired - Lifetime
  • 2002-01-17 CA CA2433417A patent/CA2433417C/en not_active Expired - Lifetime
  • 2002-01-17 EP EP02716007A patent/EP1368306B1/de not_active Expired - Lifetime
  • 2002-01-17 JP JP2002557901A patent/JP4230770B2/ja not_active Expired - Lifetime
• 2009
  • 2009-02-11 US US12/369,595 patent/US8487009B2/en not_active Expired - Lifetime
  • 2009-07-14 HK HK09106335.2A patent/HK1128679A1/xx not_active IP Right Cessation

Patent Citations (2)

Also Published As

Similar Documents

Legal Events